HOME >> BIOLOGY >> NEWS
Treating precancerous breast cells may prevent onset of cancer

Boston, MA (October 17, 2002) Treating precancerous breast cells with chemopreventive agents, such as tamoxifen, limits the development of breast cancer in genetically predisposed women, according to a study presented at the American Association for Cancer Research's (AACR) annual Frontiers in Cancer Prevention meeting. Precancerous breast cells may also provide an effective mechanism for screening new and current chemopreventive agents.

The study used precancerous breast cells from patients with Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition syndrome associated with a number of childhood cancers and the early onset of breast cancer. Unlike most human cancer cells, LFS cells become cancerous at more measurable rates in vitro (a closed environment, e.g. test tube), and are therefore easier to monitor. Individuals with LFS are at increased risk for developing multiple primary cancers, including soft-tissue sarcoma, breast cancer, leukemia, osteosarcoma, melanoma and colorectal cancers.

"To effectively treat or prevent cancer, it is important to understand the nature of how cells progress into the disease," explained Brittney-Shea Herbert, Ph.D., cell biologist at The University of Texas Southwestern Medical Center, Dallas, and lead investigator of the study. "Results from human clinical trials take many years to generate so it is imperative that alternate testing forms, such as precancerous cells, be used to determine the effectiveness of precancerous agents."

Treatment of precancerous LFS breast cells with some but not all chemopreventive agents decreased the development of cancer in vitro. The chemopreventive agents used in this study did not negatively affect normal cell growth, nor result in notable side effects from the treatment. Tamoxifen had the strongest effect in preventing the frequency of cell immortalization, at nontoxic levels.

Precancerous cells were treated with tolerable levels of tamoxifen,
'"/>

Contact: Aimee Frank
AMF@spectrumscience.com
202-369-1654
American Association for Cancer Research
17-Oct-2002


Page: 1 2

Related biology news :

1. Treating strokes with blood cord cells holds promise, Saint Louis University rat study shows
2. Treating bacterial infections can help asthmatics
3. Treating metastatic disease with a modified herpesvirus
4. Treating acne with antibiotics leads to resistance
5. Study Provides Guidance For Treating Patients With Brain Aneurysms
6. Relapses Prevented In Mouse Model Of Multiple Sclerosis: Research Aimed At Treating Relapses In Human MS
7. Mechanism Of Protein Folding Unraveled, With Eventual Implications For Treating Diseases Caused By Folding Errors
8. Gene Therapy In A Liquid May Lead To Quicker, Easier Methods For Treating Disease
9. New Class Of Protease Inhibitors May Be Effective In Treating One Of Latin Americas Most Devastating Diseases
10. Study Finds Shorter Period Of Drug Therapy Is Effective In Treating Stomach Ulcers Caused By H. Pylori
11. Treating Anemia Reduces Risk Of Death For People With HIV

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Treating precancerous breast cells may prevent onset cancer

(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: